Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
BOTHELL, Wash., Feb. 09, 2017 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that it will webcast its presentation at the upcoming Leerink Partners 6th Annual Global Healthcare Conference at 1:00 p.m. ET (10:00 a.m. PT) on Thursday, February 16, 2017 in New York, NY. The presentation will feature a business overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.
A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for 30 days after the live event concludes.
Link: http://wsw.com/webcast/leerink28/aldr
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.
Media Contacts: David Schull or Victoria Meissner Russo Partners, LLC (212) 845-4271 (646) 942-5627 [email protected] [email protected] Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 [email protected]
